NASDAQ:ADXS Ayala Pharmaceuticals (ADXS) Stock Price, News & Analysis $0.03 0.00 (0.00%) As of 07/25/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock About Ayala Pharmaceuticals Stock (NASDAQ:ADXS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Ayala Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.03▼$0.0350-Day Range$0.03▼$0.1552-Week Range$0.00▼$0.78Volume14 shsAverage Volume5,281 shsMarket Capitalization$1.48 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware. Read More Receive ADXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ayala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ADXS Stock News HeadlinesAyala Pharmaceuticals, Inc. (ADXS) - Yahoo FinanceJune 27, 2025 | finance.yahoo.comRockville's OS Therapies acquires rights to key drugs, eyes FDA approval for cancer therapyFebruary 5, 2025 | bizjournals.comI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before the open. That’s the kind of move Tim Sykes built his XGPT system to trade. It scans AI news in real time, filters the noise, and pinpoints when to strike. He’s now showing exactly how it works — before the next headline hits.July 26 at 2:00 AM | Timothy Sykes (Ad)OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to PipelineJanuary 29, 2025 | businesswire.comAyala unit expands cold storage networkSeptember 4, 2024 | msn.comAyala explores minority stake sale in AC Health, sources sayAugust 1, 2024 | msn.comAyala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting ObligationsMay 9, 2024 | globenewswire.comImmunome: An Oncology Powerhouse In The MakingApril 2, 2024 | seekingalpha.comSee More Headlines ADXS Stock Analysis - Frequently Asked Questions How have ADXS shares performed this year? Ayala Pharmaceuticals' stock was trading at $0.0270 on January 1st, 2025. Since then, ADXS shares have increased by 28.5% and is now trading at $0.0347. How were Ayala Pharmaceuticals' earnings last quarter? Ayala Pharmaceuticals, Inc. (NASDAQ:ADXS) issued its quarterly earnings results on Thursday, September, 9th. The company reported ($0.02) EPS for the quarter, beating analysts' consensus estimates of ($0.04) by $0.02. The firm earned $0.25 million during the quarter. How do I buy shares of Ayala Pharmaceuticals? Shares of ADXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ayala Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ayala Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), Madrigal Pharmaceuticals (MDGL), Merck & Co., Inc. (MRK), Acasti Pharma (ACST), Bristol Myers Squibb (BMY) and Company Calendar Last Earnings9/09/2021Today7/26/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADXS CIK1100397 Webwww.ayalapharma.com Phone609-452-9813Fax609-452-9818Employees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$3.24 million Price / Sales0.46 Cash FlowN/A Price / Cash FlowN/A Book Value($2.06) per share Price / Book-0.02Miscellaneous Outstanding Shares42,633,000Free Float42,364,000Market Cap$1.48 million OptionableNot Optionable Beta1.17 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:ADXS) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ayala Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ayala Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.